1. Home
  2. PMAX vs TCRT Comparison

PMAX vs TCRT Comparison

Compare PMAX & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Powell Max Limited

PMAX

Powell Max Limited

HOLD

Current Price

$2.18

Market Cap

8.1M

Sector

N/A

ML Signal

HOLD

Logo Alaunos Therapeutics Inc.

TCRT

Alaunos Therapeutics Inc.

HOLD

Current Price

$2.60

Market Cap

6.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMAX
TCRT
Founded
2019
1998
Country
Hong Kong
United States
Employees
53
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.1M
6.7M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
PMAX
TCRT
Price
$2.18
$2.60
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.4M
12.3K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
24.66
EPS
N/A
N/A
Revenue
N/A
$15,900,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$1.67
52 Week High
$5.20
$5.48

Technical Indicators

Market Signals
Indicator
PMAX
TCRT
Relative Strength Index (RSI) 63.34 41.98
Support Level $1.61 $2.59
Resistance Level $2.87 $2.84
Average True Range (ATR) 0.29 0.14
MACD 0.04 -0.01
Stochastic Oscillator 72.01 47.00

Price Performance

Historical Comparison
PMAX
TCRT

About PMAX Powell Max Limited

Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.

About TCRT Alaunos Therapeutics Inc.

Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.

Share on Social Networks: